Product details

This is the third of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes Chiron, a preeminent biotechnology firm based in California. During the period 1998-1999, Chiron targeted three healthcare segments: cancer, infectious diseases, and cardiovascular diseases. Sales broke down into three areas: biopharmaceuticals, vaccines, and blood testing. The case provides an overview of these key areas, including research and development for each. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.